About Rivaroxaban API
Therapeutic CategoryCardiovascular
CAS Number
366789-02-8
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted, Brazil DMF, Canada DMF, Russia DMF
Mechanism of Action
XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.
Indication
XARELTO is a factor Xa inhibitor indicated:
- To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- For the treatment of deep vein thrombosis (DVT)
- For the treatment of pulmonary embolism (PE)
- For the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months
- For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery
Related APIs
Amlodipine Besylate
Cardiovascular
Apixaban
Cardiovascular
Bempedoic Acid
Cardiovascular
Clopidogrel Bisulfate (Form 1)
Cardiovascular
Clopidogrel Bisulfate (Form 2)
Cardiovascular
Dabigatran Etexilate Mesylate
Cardiovascular
Doxazosin Mesylate
Cardiovascular
Ezetimibe
Cardiovascular
Fondaparinux Sodium
Cardiovascular
Lacidipine
Cardiovascular
Losartan Potassium
Cardiovascular
Mavacamten
Cardiovascular
Metoprolol Succinate
Cardiovascular
Ramipril
Cardiovascular
Rivaroxaban
Cardiovascular
Tafamidis Free Acid
Cardiovascular
Tafamidis Meglumine
Cardiovascular
Ticagrelor
Cardiovascular
Treprostinil
Cardiovascular
Treprostinil Olamine
Cardiovascular
Valsartan
Cardiovascular
Atorvastatin Calcium (Amorphous And Form P)
Cardiovascular
Sacubitril-Valsartan
Cardiovascular
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
FAQs
It is a cardiovascular drug used to treat Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism.
-
The safety dose for Rivaroxaban is 2.5, 10, 15 & 20 mg
-
Circulating levels of rivaroxaban based on its anticoagulant action.
-
We offer Form-I of Rivaroxaban API
-
Meet with our product experts in one-on-one virtual sessions at https://api.drreddys.com/meet-api-experts or Write to us at [email protected].
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.